Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | KHK | P50053 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270004 | 1.00 | KDM4E (0.56) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| Hydrochloric Acid SCHEMBL3379409 | 0.98 | KDM4E (0.55) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| SCHEMBL13052911 | 0.87 | CYP11B2 (0.55) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| SCHEMBL29741044 | 0.86 | CYP11B2 (0.51) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| Propionic Acid SCHEMBL4552402 | 0.85 | KMO (0.51) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| SCHEMBL1880811 | 0.84 | NR3C1 (0.55) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| SCHEMBL29399064 | 0.84 | NR3C1 (0.55) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| SCHEMBL20603936 | 0.84 | MGAM (0.49) | KDM4ECYP11B2CYP11B1KHKMGAM | |
| SCHEMBL29496849 | 0.84 | NR3C1 (0.65) | CYP11B2MGAMGAASIMGAM2 | |
| SCHEMBL19780904 | 0.84 | NPC1 (0.61) | KDM4ECYP11B2CYP11B1KHKMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024088110-A1 | HETEROCYCLIC MACROCYCLIC COMPOUND CONTAINING INDAZOLE STRUCTURE AND USED AS PROTEIN KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR | 复旦大学 | 2024-05-02 | — | — | WO | claimed |
| EP-3010064-B1 | SPACE-THROUGH CHARGE TRANSFER COMPOUND, AND ORGANIC LIGHT EMITTING DIODE AND DISPLAY DEVICE USING THE SAME | LG DISPLAY CO LTD (KR) | 2017-07-19 | — | — | EP | claimed |
| CN-101128559-A | Phosphorescent OLEDs with exciton blocking layer | EASTMAN KODAK CO (US) | 2008-02-20 | — | — | CN | claimed |
| EP-0934307-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1999-08-11 | — | — | EP | claimed |
| WO-1997048697-A1 | SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE | RHONE-POULENC RORER LIMITED (GB) | 1997-12-24 | — | — | WO | claimed |
| CN-122036606-A | Synthesis method of aminoacridine compound | 南京工业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-11917908-B2 | Organic compound, optical device, light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11917908-B2 | Organic compound, optical device, light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11878977-B2 | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2023190219-A1 | ORGANIC METAL COMPLEX, AND ORGANIC LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, IMAGING DEVICE, ELECTRONIC EQUIPMENT, LIGHTING DEVICE, AND MOBILE OBJECT EACH CONTAINING ORGANIC METAL COMPLEX | キヤノン株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| CN-116332851-A | Cyanomethyl phenyl indazole compound and preparation method thereof | 河南中医药大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-1331076-A | Fused pyrazolyl compounds, compositions containing the same, and uses of the compounds | YONGXIN MEDICINE INDUSTRY CO L (CN) | 2002-01-16 | — | — | CN | disclosed |
| WO-2001046104-A1 | BIS(4-HYDROXYARYL)ALKANES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0197495-B1 | 4,5,6,7-TETRAHYDRO-2H-INDAZOLE DERIVATIVES AND HERBICIDES CONTAINING THEM | SHIONOGI & CO., LTD. (JP) | 1990-07-11 | — | — | EP | disclosed |
| EP-0150419-B1 | 2H-v-triazolyl[4,5-b]pyridines and their use | BASF Aktiengesellschaft (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4695312-A | 4,5,6,7-tetrahydro-2H-indazole derivatives and herbicides containing them | SHIONOGI & CO., LTD. (JP) | 1987-09-22 | — | — | US | disclosed |
| EP-0197495-A1 | 4,5,6,7-Tetrahydro-2H-indazole derivatives and herbicides containing them | SHIONOGI & CO., LTD. (JP) | 1986-10-15 | — | — | EP | disclosed |
| EP-0162216-A1 | 2,4,5-Triphenyl-1,2,3-triazoles and thier use | BASF Aktiengesellschaft (DE) | 1985-11-27 | — | — | EP | disclosed |
| EP-0150419-A1 | 2H-v-triazolyl[4,5-b]pyridines and their use | BASF Aktiengesellschaft (DE) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878977-B2 | JAK inhibitors containing a 4-membered heterocyclic amide | JAK1, JAK2, JAK3 | KDM4E 282/4885CYP11B2 1056/4885CYP11B1 1002/4885 |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | KDM4E 1916/4885CYP11B2 3099/4885CYP11B1 2481/4885 |
| US-11917908-B2 | Organic compound, optical device, light-emitting device, light-emitting apparatus, electronic device, and lighting device | NR2E3, AOX1, CYP1A1 | KDM4E 4241/4885CYP11B2 180/4885CYP11B1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.